GUEST COLUMNISTS

• Turning Pediatric Cancer Discoveries Into Medicines Requires Better Connections

  Promising pediatric cancer science often stalls before patients benefit. David Adler explains how better connections could change that.

• Turning A Historically Limited Modality Into A Respiratory Drug Opportunity

  How can sponsors revive a promising modality with known safety limits? Vast Therapeutics CEO Nate Stasko, Ph.D., explains how ALX1 is reshaping nitric oxide delivery.

• It Is Time To Require Human-Relevant Efficacy Evidence Before First-In-Human Trials

  Why, when human-relevant evidence of likely efficacy can be generated before a trial begins, is it not evaluated before patients are exposed?

• Immune Priming, Oncolytic Viruses, And The Next Phase Of Solid Tumor Immunotherapy

  Can priming with oncolytic viruses be a better path to reeducating the immune system to recognize and attack cancer? Oncolytics Biotech advisor Richard Vile, Ph.D., says yes.

• 4 Ways That AI And Point-Of-Care Diagnostics Are Redefining Clinical Trial Design And Operations

  Discover how AI-enhanced point-of-care diagnostics are changing trial design and what ClinOps should do next.

• What BriaCell's Trial Design Says About Real-World Cancer Research

  BriaCell President and CEO William Williams, MD, shares how broader eligibility criteria and physician’s choice controls can better reflect real-world cancer care.

• Accountability Gaps Can Break Clinical Supply Contracts

  Contract gaps can create clinical supply failures when responsibilities differ across agreements. See how aligning obligations can prevent costly disputes, delays, and risks.

• 'How Do You Feel?': Designing A Cardiac Trial With A Patient-Reported Primary Endpoint

  Imbria Pharmaceuticals' Albert Kim, MD, Ph.D., shares why PROs are the point of the company's FORTITUDE-HCM trial for patients with non-obstructive hypertrophic cardiomyopathy.